Orum Therapeutics is a public biotechnology company developing degrader-antibody conjugates (DACs) to deliver protein degraders to specific cells and eliminate proteins that drive disease. Its lead program, ORM-1153, targets CD123 to deliver a GSPT1 degrader to cancer cells in acute myeloid leukemia and other hematologic malignancies. Orum is also developing new DAC payload platforms beyond GSPT1 to broaden the targets and diseases it can pursue across oncology and other therapeutic areas.
Orum Therapeutics is a public biotechnology company developing degrader-antibody conjugates (DACs) to deliver protein degraders to specific cells and eliminate proteins that drive disease. Its lead program, ORM-1153, targets CD123 to deliver a GSPT1 degrader to cancer cells in acute myeloid leukemia and other hematologic malignancies. Orum is also developing new DAC payload platforms beyond GSPT1 to broaden the targets and diseases it can pursue across oncology and other therapeutic areas.